News
Azora Therapeutics Will Present at Scientific and Investor Conferences in 2023
Los Angeles CA - December 12, 2022 - Azora Therapeutics Inc., a biopharmaceutical company focused on developing treatments for serious inflammatory diseases, announces that they will be presenting at a number of scientific and investor conferences in 2023. Azora is excited about a number of key milestones in 2023 including clinical read outs from our proof-of-concept topical studies of AT193 and advancement of our novel oral program AT177 for ulcerative colitis.
Please connect with us:
January 8th 2023 @ Dermatology Summit at JPM - Speaking at 5:15pm
January 9th-11th 2023 @ Biotech Showcase at JPM - Speaking January 10th at 10:30am
January 10th 2023 @ RESI at JPM
January 19th-21st 2023 @ Crohn's and Colitis Congress in Denver - Poster Presentation
February 28th-March 2nd @ BioCom Partnering Conference in San Diego
We welcome partnership, collaboration and investment opportunities for both AT177 and/or AT193.
About Azora
Azora Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was spun out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns the worldwide royalty-free rights to its technology, which is based on the development of potential best-in-class and first-in-class oral and topical agonists of the aryl hydrocarbon receptor. More information on Azora and its pipeline can be found on the company's website at www.AzoraTherapeutics.com.
Azora Therapeutics Announces the Publication of Positive Phase 1b Study Results in Treatment-Refractory Ulcerative Colitis
Los Angeles CA - January 3, 2022 - Azora Therapeutics Inc., a biopharmaceutical company focused on developing treatments for serious inflammatory diseases, announces the publication of Phase 1b study results in patients with treatment-refractory ulcerative colitis in BMJ Open Gastroenterology.
The manuscript, titled “Treatment-refractory ulcerative colitis responsive to indigo naturalis” was published online in the December 30, 2021 BMJ Open Gastroenterology.
Results from the phase 1b open-label trial, conducted at Stanford University, showed that 10/11 patients with treatment-refractory ulcerative colitis, including some recommended for colectomy (surgical removal of the colon), met the primary endpoint of clinical response after 8 weeks of treatment with oral indigo naturalis. All study patients experienced improved endoscopic severity and quality of life. The therapy was well tolerated with no discontinuations due to adverse events. In addition, all evaluable patients demonstrated a dramatic reduction in colon inflammation via a biomarker (fecal calprotectin). Colon biopsies at week 8 demonstrated a significant increase (greater than 10,000-fold) in aryl hydrocarbon receptor activation as evaluated by CYP1A1 mRNA expression.
Indigo naturalis is a botanical extract that contains molecules that are agonists of the aryl hydrocarbon receptor. This is the same mechanism of action as Azora's AT193, a topical treatment currently being studied in ongoing clinical trials for hidradenitis suppurativa and nail psoriasis and Azora's AT177 an oral treatment currently in development.
“We are enthusiastic with the positive results of the study and the solid foundation we believe it may provide for conducting further trials to evaluate options for patients with treatment-refractory ulcerative colitis” added Berkeley N Limketkai, MD, PhD, the lead investigator of the study and currently Director of Inflammatory Bowel Disease Clinical Research at University of California at Los Angeles (UCLA).
The study was conducted with funding provided by SPARK at Stanford, Weston Havens Foundation, and Azora Therapeutics.
About Azora
Azora Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was spun out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns the worldwide royalty-free rights to its technology, which is based on the development of potential best-in-class and first-in-class oral and topical agonists of the aryl hydrocarbon receptor. More information on Azora and its pipeline can be found on the company's website at www.AzoraTherapeutics.com.
Azora Therapeutics Enrolls First Patient in Clinical Trial of AT-193, a Potential Treatment for Hidradenitis Suppurativa
Los Angeles CA - October 19, 2021 - Azora Therapeutics Inc., a biopharmaceutical company focused on developing treatments for serious inflammatory diseases, announced today that the first patient has been enrolled in trial HS01, a phase 1b multicenter, randomized, double-blind, placebo-controlled study of topical AT193 for the treatment of mild-to-moderate hidradenitis suppurativa (HS). The study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of AT-193 and is expected to enroll 40 patients with mild-to-moderate HS at multiple sites in Australia.
Hidradenitis suppurativa (HS) is a debilitating, chronic autoinflammatory disease affecting the apocrine gland-bearing skin. HS typically manifests as painful inflammatory nodules in the armpits, breasts, groin, and buttocks. Sustained inflammation contributes to the formation of abscesses, fistulas, and sinus tracts. Disease can be progressive, ranging from mild to severe, and can span decades in duration. The pathology of HS is poorly understood but involves microbial dysbiosis and an autoinflammatory response. Patients with HS have significantly impaired quality of life due to physical and psychological discomfort associated with the disease. There are no FDA-approved medications for the treatment of mild-to-moderate HS.
“Patients with mild-to-moderate HS may have fewer nodules or abscesses, but they still cause considerable pain and have the potential to rupture and drain onto clothing. A treatment option for these patients, preferably a convenient topical therapy, is sorely needed" stated Dr. Martin Okun, Azora Clinical Advisor and HS expert who helped design the pivotal phase 3 trials of adalimumab (Humira®) for moderate-to-severe HS that resulted in the first and only FDA-approved product for the disease.
About Azora
Azora Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was spun out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns the worldwide royalty-free rights to its technology, which is based on the development of potential best-in-class and first-in-class oral and topical agonists of the aryl hydrocarbon receptor. More information on Azora and its pipeline can be found on the company's website at www.AzoraTherapeutics.com.
Azora Therapeutics Completes $8M Series A Financing
Los Angeles CA - June 1, 2021 - Azora Therapeutics Inc., a biopharmaceutical company focused on developing treatments for serious inflammatory diseases, announced the closing of a $8M Series A financing. Acclaimed Stanford University Medical School Professors and biotech founders participated in the round including the founders of Forty-Seven Therapeutics, Dendreon, and Neurocrine Biosciences.
Proceeds from the Series A will support the advancement of Azora's topical and oral programs for the treatment of Hidradenitis Suppurativa (HS), Ulcerative Colitis (UC), and unspecified programs. The company expects to begin clinical trials for HS Q4 2021.
Concurrent with the close of the financing, Azora announced that biotech veteran Dennis Brown, PhD, founder of ChemGenex Therapeutics, Matrix Pharmaceutics, and Kintara Therapeutics, has been nominated to join Azora's Board of Directors. "Dr. Brown has been a long time advisor and has more than thirty years of drug discovery and development experience. We welcome his creativity and strategic direction as we take Azora into its next stages," stated Matt Davidson, PhD, Chief Executive Officer of Azora.
About Azora
Azora Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was spun out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns the worldwide royalty-free rights to its technology, which is based on the development of potential best-in-class and first-in-class oral and topical agonists of the aryl hydrocarbon receptor. More information on Azora and its pipeline can be found on the company's website at www.AzoraTherapeutics.com.